10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam
23 August 2009. Related: Conference reports, Conference index, PK Workshop 10th 2009.
The following early reports from the conference are included thanks to natap.org:
- Genetic markers linked to early discontinuation of three antiretrovirals
- Efavirenz lowers levels of darunavir given as 900/100 mg once daily with ritonavir
- How much (or how little) ritonavir do you need to boost another PI?
Other reports in this issue are:
- Monotherapy study may explain previous poor clinical results when abacavir and tenofovir are used in combination
- Interactions between ARVs and the antimalarials atovaquone and proguanil
- Four weeks lopinavir/r to cover functional monotherapy when stopping HAART
- Efavirenz-related studies: genetics, smoking and TDM
- Atazanavir: a suitable case for TDM?
- Raltegravir PK in blood plasma and the genital tract
- A CYP2B6 haplotype influences nevirapine plasma concentrations following a single dose to reduce mother to child transmission
- Population pharmacokinetic model of nevirapine maternal to infant transfer through breastfeeding
- Phenotypic and genotypic inhibitory quotients and virologic response in treatment experienced children
- Tenofovir pharmacokinetics in three tenofovir-containing regimens in children and adolescents
- Bioavailability of Thai generic lopinavir/ritonavir
It is disappointing that the abstracts from the virology-education meetings are not published online, and that only a selection of presentations from the meeting are available at:
A useful summary report of the drug-interaction studies presented at the meeting is available on the Liverpool University website (in the April 2009 news archive):